Skip to main content

Table 1 Patients´ characteristics

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

Characteristicn = 32
Sex n (%)
 male21 (66)
 female11 (34)
Age (years)
 median63
 range44–81
Stadium n (%)
 localized10 (31)
 metastasized22 (69)
Grading n (%)
 G2, G322 (69)
 G17 (22)
 Gxa3 (9)
Cycles of doxorubicin/olaratumab administered n (%)
 1 to 523 (72)
 6 to 89 (28)
 median no. of cycles4
Exposure to doxorubicin
 median cumulative dose (mg/m2)300
 range (mg/m2)75–600
Proportion of patients with delay of therapy due to toxicity/infection n (%)4 (12,5)
Patients with previous treatment lines n (%)
 025 (78)
  ≥ 17 (32)
Response n (%)
 PR4 (13)
 SD7 (22)
 PD21 (66)
Performance status (ECOG) n (%)
 014 (44)
 116 (50)
 22 (6)
Pattern of metastases n (%)
 lung only3 (9)
 multiple6 (19)
Site of primary tumor n (%)
 extremity8 (25)
 retroperitoneum8 (25)
 trunc14 (4)
 head1 (3)
 uterus1 (3)
Site of metastasis n (%)
 lung6 (19)
 liver4 (13)
 bone2 (6)
 other7 (22)
  1. PR partial remission; SD stable disease; PR progressive disease
  2. ano formal grading available, but with clear histologic and radiologic features of high grade sarcoma